Nimish Patel, Pharm.D., Ph.D., AAHIVP



  • Ph.D., Epidemiology, SUNY School of Public Health, Albany, NY
  • M.S., Epidemiology, SUNY School of Public Health, Albany, NY
  • Infectious Diseases Outcomes Fellow, Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY
  • HIV Specialty Pharmacy Resident, University Health Network – Toronto General Hospital, McGill University Health Centre – L’Institut Thoracique, Toronto, ONT
  • Pharm.D., Albany College of Pharmacy and Health Sciences, Albany, NY

Research Interests

  • Pharmacoepidemiology & Clinical Outcomes Research
  • Study design and methods 
  • Infectious diseases 
  • Hospital-acquired infections
  • HIV/AIDS treatment outcomes & predictors of response
  • Hepatitis B vaccine response among special populations
  • Hepatitis C treatment outcomes and predictors of response

Honors and Achievements

  • Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Infectious Diseases Fellows Grant Program (2009).
  • Infectious Diseases Society of America, Fellows Travel Grant Recipient. Awarded to infectious diseases fellows in recognition of excellence in abstract submission to the IDSA Annual Meeting (2009).

Selected Publications

Patel N, Nasiri M, Koroglu A, Bliss S, Davis M, McNutt LA, Miller CD. Comparing the Frequency of Drug Interactions after Adding Simeprevir- or Sofosbuvir-containing therapy to Medication Profiles of Hepatitis C Monoinfected Patients: A Quantitative Analysis to Aid in Selecting Therapy. Infect Dis Ther. 2015 Jan 28. [Epub ahead of print].

Nugmanova Z, Patel N, Nurbakhyt A, Akhmetova GM, Kovtunenko NS, Trumova Z, McNutt LA. Universal precautions in Central Asia: the need for multiple strategies in this window of opportunity. J Hosp Infect. 2015 Mar;89(3):197-201. doi: 10.1016/j.jhin.2014.11.011. Epub 2014 Dec 24.

Patel N, Nasiri M, Koroglu A, Amin R, McGuey L, McNutt LA, Roman M, Miller CD. Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment among HIV and hepatitis C coinfected patients. AIDS Res Hum Retroviruses. 2015 Feb;31(2):189-97. doi: 10.1089/AID.2014.0215. Epub 2015 Jan 6.

McConnell HL, Perris ET, Lowry C, Lodise T, Patel N. Effect of Concomitant 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Therapy on Creatine Phosphokinase Levels and Mortality Among Patients Receiving Daptomycin: Retrospective Cohort Study. Infect Dis Ther. 2014 Sep 23. [Epub ahead of print]

Patel N, Veve M, Nasiri M, Bliss S, McNutt LA, Lazariu V, Miller C. Predicting the Probability of Experiencing Clinically Significant Drug-Drug Interactions Involving Boceprevir-Containing Hepatitis C Therapy Among Patients Coinfected with Hepatitis C and HIV. AIDS Patient Care STDS. 2014 Oct;28(10):513-6. doi: 10.1089/apc.2014.0149. Epub 2014 Aug 5.

Patel N, Veve MP, Bliss S, Nasiri M, McNutt LA, Lazariu V, Roman M, Miller CD. Prevalence and predictors of important telaprevir drug interactions among patients co-infected with hepatitis C and human immunodeficiency virus. J Pharm Technol. 2014 October: 159-167. doi: 10.1177/8755122514533941.

Lodise TP, Patel N, Rivera A, Tristani L, Lazariu V, Vandewall H, McNutt LA. Comparative evaluation of serotonin toxicity among veterans affairs patients receiving linezolid and vancomycin. Antimicrob Agents Chemother. 2013 Dec;57(12):5901-11. doi: 10.1128/AAC.00921-13. Epub 2013 Sep 16.

Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, Laplante KL, Potoski BA, Rybak MJ. Clinical outcomes in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) bloodstream infection. Antimicrob Agents Chemother. 2013 Jun 24. [Epub ahead of print]

Patel N, Veve M, Kwon S, McNutt LA, Fish D, Miller C. Frequency of electrocardiogram testing among HIV-infected patients at risk for medication-induced QTc prolongation. HIV Med. 2013 Sep;14(8):463-71. doi: 10.1111/hiv.12031. Epub 2013 Mar 18.

Butterfield JM, Mueller B, Patel N, Cardone K, Grabe DW, Salama N, Lodise TP. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis. Antimicrob Agents Chemother. 2013 Feb;57(2):864-72. doi: 10.1128/AAC.02000-12. Epub 2012 Dec 3.

Miller S, Patel N, Vadala T, Abrons J, Cerulli J. Defining the pharmacist role in the pandemic outbreak of novel H1N1 influenza. J Am Pharm Assoc (2003). 2012 Nov 1;52(6):763-7. doi: 10.1331/JAPhA.2012.11003.

Patel N, Harrington S, Dihmess A, Woo B, Masoud R, Martis P, Fiorenza M, Graffunder E, Evans A, McNutt LA, Lodise TP. Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae. J Antimicrob Chemother. 2011 Jul;66(7):1600-8. Epub 2011 Apr 19.

Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: We Can't Get There from Here. Clin Infect Dis. 2011 Apr;52(8):969-74.

Cardone KE, Lodise TP, Patel N, Hoy CD, Meola S, Manley HJ, Drusano GL, Grabe DW. Pharmacokinetics and Pharmacodynamics of Intravenous Daptomycin during Continuous Ambulatory Peritoneal Dialysis. Clin J Am Soc Nephrol. 2011 May;6(5):1081-8. Epub 2011 Mar 10.

Patel N, , Veve M, Miller CD. Predictors of Clinically Significant Drug-Drug Interactions among Patients Treated with Non-nucleoside Reverse Transcriptase inhibitor-, Protease Inhibitor-, and Raltegravir-based Antiretroviral Regimens. Ann Pharmacother. 2011 Mar;45(3):317-24. Epub 2011 Mar 8.

Patel N, Cardone K, Grabe DW, Meola S, Hoy C, Manley H, Drusano GL, Lodise TP. Use of Pharmacokinetic and Pharmacodynamic Principles to Determine Optimal Administration of Daptomycin in Patients Receiving Standardized Thrice Weekly Hemodialysis. Antimicrob Agents Chemother. 2011 Apr;55(4):1677-83. Epub 2011 Jan 31.

Patel N, Scheetz MH, Drusano GL, Lodise TP. Identification of Optimal Renal Dosage Adjustments for Traditional and Extended Infusion Piperacillin/Tazobactam Dosing Regimens in Hospitalized Patients. Antimicrob Agents Chemother. 2010 Jan;54(1):460-5. Epub 2009 Oct 26.

Patel N, Lubanski P, Ferro S, Bonafede M, Harrington S, Evans A, Stellrecht K, Lodise TP. Correlation Between Vancomycin MIC Values and the MIC Values of Other Gram-positive Agents Among Patients with MRSA Bloodstream Infections. Antimicrob Agents and Chemother. 2009 Dec;53(12):5141-4. Epub 2009 Oct 5.

Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between Initial Vancomycin Concentration-Time Profile and Nephrotoxicity among Hospitalized Patients. Clin Infect Dis. 2009 Aug 15;49(4):507-14.

Patel GP, Simon D, Scheetz M, Crank CW, Lodise T, Patel N. The Effect of Time to Antifungal Therapy on Mortality in Candidemia Associated Septic Shock Am J Ther. 2009 Nov-Dec;16(6):508-11.

Patel GW, Patel N, Lat A, Trombley KC, Enbawe S, Smith R, Lodise TP. Outcomes of Extended Infusion Piperacillin/Tazobactam for Documented Gram-negative Infections. Diag Microbio Infect Dis. 64 (2009) 236–240.

Assistant Professor
Department of Pharmacy Practice